Everbridge Features 43rd President of the United States George W. Bush Speaking on Leadership and Critical Event Management, as well as CNN’s Dr. Sanjay Gupta as Day 1 Keynote for COVID-19: Road to Recovery Symposium
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced highlights from day one of its two-day Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership symposium, addressing global best practices to reopen economies amid COVID-19, while most safely returning people to public spaces, offices and campuses. The first day’s sessions emphasized the importance of public and private sector partnerships during the next phase of the pandemic. Day two of the symposium offers another impressive lineup of marquee speakers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005454/en/
Everbridge COVID-19 Symposium Autumn 2020 (Graphic: Business Wire)
Everbridge’s COVID-19: Road to Recovery Symposiums bring together tens of thousands of leaders and experts from 150 countries across business, healthcare, and government. To attend the “COVID-19 R2R: The Road to Recovery” virtual leadership summit and to replay select presentations on demand, please visit Everbridge’s event registration page.
In his conversation with Everbridge CEO David Meredith, President Bush shared his perspective on leadership and critical event management during a public health crisis, as he addressed leaders across industries. He also emphasized the value of preparedness for crises of all kinds, including pandemics, severe weather, cyber-attacks and more.
“We at Everbridge feel privileged to feature the 43rd President of the United States George W. Bush to speak on leadership and critical event management during the first day of our COVID-19: Road to Recovery Symposium,” said Everbridge CEO David Meredith. “Joined by CNN’s Dr. Sanjay Gupta, day one of our event included board level, CEO, president and C-level speakers from Capital One, Fannie Mae, Ford, Fortinet, Humana, IBM, Mayo Clinic and more.”
Added Meredith, “While we all await a vaccine, global leaders, including many of our keynote speakers and panelists, strive to utilize innovative technologies, as well as proven best practices to take immediate action to keep their people as safe as possible while also getting their organizations up and running, faster. We can draw inspiration and hope from the many stories shared this week on navigating the uncertainty of returning to work and reopening society, safely.”
Day one highlights also included discussions with Director of the Center for the National Center for Immunization and Respiratory Diseases (NCIRD) Dr. Nancy Messonnier; a panel with board members representing Fortinet, DOW, Russell Reynolds Associates, Tyson Foods, and others; as well as a panel dedicated to C-level leadership, including IBM President Jim Whitehurst and Ford Motor Company’s former CEO Jim Hackett. Mississippi Governor Tate Reeves and former Florida Lieutenant Governor Carlos Lopez-Cantera spoke from a government leadership perspective, and day one also included a debut speech from newly appointed Everbridge Chief Customer Experience Officer John Maeda. Each of these sessions can be found on-demand on the Everbridge site.
Day two (October 15th) keynote speakers will include presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci and Virgin Group Founder Sir Richard Branson and many other C-level leaders across public and private sectors.
The Symposium features C-level speakers from Fortune 500 and international corporations, universities, healthcare organizations and government agencies including Ford Motor Company, IBM, Fortinet, Accenture, Auburn University, Aviva, CAG Holdings, Capital One, Fannie Mae, Humana, Lumen Technologies, Optum, Rackspace, Siemens, Mayo Clinic, Kaiser Permanente, Los Angeles World Airports (LAWA), Goldman Sachs, the Governor of Mississippi, the Mayor of Miami, Houston Methodist Hospital, CDC Foundation, the Center for the National Center for Immunization and Respiratory Diseases (NCIRD), Duke University Health System, the Commonwealth of Massachusetts, New York City Emergency Management Department, Office of National Commission of Police in Iceland, the European Emergency Number Association (EENA), and Australia’s Emergency Alert program, among others.
Over 5,300 global organizations use Everbridge’s CEM Platform to assess threats, monitor the wellbeing of their workforce, rapidly communicate warnings, and protect supply chains. At the onset of the pandemic, Everbridge rapidly launched its COVID-19 Shield™ Return to Work and Contact Tracing software solutions followed by the introduction of Everbridge Control Center, the industry’s first off-the-shelf physical security information management software platform to help organizations return to work while complying with social distancing and Personal Protective Equipment (PPE) policies. Since the pandemic began, Everbridge customers have used its software to send more than 850 million coronavirus-related communications with vital information and instructions to safeguard their populations, employees, patients, and students.
Everbridge serves over 3,700 first responder agencies and 1,500 healthcare entities including the top pharmaceutical, biomedical and medical device and manufacturing companies, as well as the largest healthcare systems (overseeing more than 25 percent of all hospital beds in the U.S.), managed care organizations, pharmacies, and statewide health alert networks (HANs), including the CDC and the NIH.
The Everbridge Platform reaches over 600 million people and currently supports the countrywide public warning system deployments inall major regions of the world. Everbridge supports population-wide alerting in 11 countries across Europe, Asia, Oceania, The Middle East, Africa, and South Americaincluding Australia, Iceland, the Netherlands, New Zealand, Norway, Peru, Singapore and Sweden. Everbridge’s population alerting capabilities also power the entire states of California, Massachusetts, Vermont, New York, Connecticut, and Florida, as well as municipalities, counties and cities within 49 of the 50 United States, within all of Canada’s provinces, and throughout Europe and Asia, including deployments within multiple populous states in India.
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 14 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Process Sensing Technologies, a Battery Ventures Company, Announces New Majority Investment from AEA Investors1.12.2020 06:01:00 CET | Press release
Process Sensing Technologies (“PST”), a global manufacturer of instruments, analyzers and sensors for precision measurement and monitoring in a variety of critical industries, announced that global private-equity firm AEA Investors LP (“AEA”) has made a majority investment in the company. PST backer Battery Ventures will maintain a minority stake in the business. Baird acted as exclusive sell-side advisor; other terms of the transaction were not disclosed. PST—a platform constructed under Battery’s ownership comprising seven global businesses—sells its sensors and other technologies into industries including pharmaceuticals, life sciences, specialty gases, petrochemicals, food-and-beverage, semiconductors and building automation. The company’s products measure moisture, oxygen and pressure, among other things, and help improve customers’ profitability while helping them stay compliant with often-stringent industry regulations. Battery began the PST platform journey with its acquisition
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited1.12.2020 00:00:00 CET | Press release
Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC"). Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Eda
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific1.12.2020 00:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020. The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfol
Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ® ) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)30.11.2020 22:58:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a
Amblin Partners Announces New Multi-Year Film Distribution Partnership With Universal Filmed Entertainment Group30.11.2020 22:00:00 CET | Press release
Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman. Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratula
Little Cinema Taps Verimatrix To Secure Hollywood’s Virtual Premiere Events30.11.2020 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that New York-based Little Cinema deployed Verimatrix Watermarking and Multi-DRM technologies for its virtual premieres and previews. A groundbreaking digital studio, Little Cinema has partnered with Netflix, ABC, CBS, HBO Max, and Warner Media to produce state-of-the-art virtual premiere events for an industry that used to rely solely on in-person debuts. To fulfill the enhanced protection requirements for this high-value early-release content, Little Cinema looked to Verimatrix and its Secure Cloud. These innovative and highly-interactive virtual streaming events have made waves in Hollywood, earning the studio recognition in BBC News, Vogue, Variety, Vanity Fair, The Hollywood Reporter, and more. “Verimatrix supplies us with the needed anti-piracy protections and overall peace of mind that Hollywood studios demand when switching to virtual events